X4 Pharmaceuticals, a clinical stage biotechnology company developing a CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, announced updated results from the phase I part of an ongoing phase I/II study of X4P-001-IO in combination with Inlyta (axitinib) in patients with clear cell renal cell carcinoma.
Novartis announced positive topline results from the global MONALEESA-7 trial, the second phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer.
Genentech said the phase III IMpower150 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer.
Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.
A new type of CAR-T therapy that targets the protein CD22 helped achieve remission in nearly 60 percent of leukemia patients who had failed or relapsed on other treatments, according to a paper published in Nature Medicine.
FDA has approved Yescarta (axicabtagene ciloleucel), a genetically modified cell therapy, to treat adult patients with certain types of large B cell lymphoma who have not responded to or have relapsed after at least two other kinds of treatment.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following
Argos Therapeutics Inc. reported on an update on the interim analysis of data from the ongoing phase III ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma was presented by Robert Figlin, professor and chairman, division of hematology and oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid.
Pfizer Inc. and Astellas Pharma Inc. announced the phase III PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.
A new Cleveland Clinic study underscores the importance of early detection and treatment of melanoma, the deadliest form of skin cancer.
